SS-31
SS-31 is elamipretide, the medicine approved as Forzinity for Barth syndrome. Human trials answer different questions, and none of the evidence here establishes an anti-aging treatment.
- U.S. status
- Approved brand; coverage restricted
- Forzinity (elamipretide) received accelerated approval on September 19, 2025, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. It is a subcutaneous injection; confirmatory evidence of clinical benefit is required. This is not a longevity indication. Only the approved branded product is covered here; this coverage limit does not establish that every compounded preparation is prohibited or permitted.
- FDA source, read October 2026.Also:FDA Forzinity trial snapshot and prescribing informationFDA 503A bulk-substance conditions
- Evidence cited here
- Longevity: no cited study measured this, so no label
- Reid Thompson 2021 (12 people), Karaa 2023 (218 people) and Roshanravan 2021 (39 people) did not measure longevity, so they count toward no label here. They are still listed with the studies below.
- Forms sold
- Brand only
- Compounded versions are not permitted, so we list no compounded seller or price.
- Eligible only as injection. No injectable form is on any FDA list.
1. What SS-31 is
SS-31 is a synthetic peptide also known as elamipretide. MTP-131 and Bendavia appear in older research. The FDA-approved medicine is Forzinity, a subcutaneous injection with a specific formulation and prescribing information.
Forzinity received accelerated approval in September 2025 to improve muscle strength in Barth syndrome. It covers adults and children who weigh at least 30 kg. It is not approved for longevity, anti-aging or general fatigue. The compound register below links the FDA sources for that distinction.
A product advertised as SS-31 has not been shown equivalent to Forzinity merely because it uses the same molecule name. Its contents, concentration, sterility and quality require separate verification. This guide does not recommend research-market sellers.
2. How it works
Elamipretide binds cardiolipin, a lipid in the inner mitochondrial membrane. That mechanism is relevant to Barth syndrome, a rare genetic disorder involving cardiolipin metabolism. A plausible mitochondrial mechanism does not establish a benefit for aging in otherwise healthy people.
The approved product's labeling includes hypersensitivity reactions, including serious reactions, and injection-site reactions. Its precautions and patient-specific prescribing requirements still apply even when a proposed use is outside the approved indication.
3. What the studies measured
The randomized Barth syndrome trial enrolled 12 participants and did not meet its walking-distance and fatigue primary endpoints. Ten entered an open-label extension. The FDA's accelerated approval relied on knee extensor muscle strength observed during the extension, with a confirmatory randomized trial required.
MMPOWER-3 studied a different population: 218 people with primary mitochondrial myopathy. After 24 weeks, neither the six-minute walk nor fatigue primary endpoint improved significantly compared with placebo.
A smaller trial in 39 older adults selected for poor mitochondrial function found a transient change in mitochondrial energetic capacity after a single infusion. The absolute-change analysis was not statistically significant, the percentage-change analysis was, and there was no difference at day seven or significant improvement in measured muscle fatigue resistance.
4. What they did not measure
These studies do not demonstrate longer life, prevention of age-related disease or sustained improvement in everyday function in healthy adults. Results in Barth syndrome cannot be generalized to an anti-aging population.
The open-label extension lacked a concurrent placebo group. Its improvements must be interpreted alongside the randomized results and the remaining requirement to confirm patient benefit.
The brand-only coverage here is an editorial limit, not a blanket determination about compounding law. An approved-drug component can fall under a different statutory route from a nominated bulk substance; the other conditions still matter for a particular preparation.
The studies behind this page
The evidence label above is computed from these papers: their design and how many people they enrolled.
- Randomized trial
12 people
Counts toward no label
Randomized walking-distance and fatigue primary endpoints were not met. The uncontrolled extension reported improvements that cannot isolate a treatment effect as reliably as a placebo comparison.
People with Barth syndrome in a randomized crossover trial followed by an open-label extension.
Reid Thompson W, Hornby B, Manuel R, et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism Genetics in Medicine. PMID 33077895
- Randomized trial
218 people
Counts toward no label
Neither primary endpoint improved significantly. The six-minute walk difference was -3.2 meters (95% confidence interval -18.7 to 12.3; p = 0.69); the fatigue endpoint was also negative.
People with genetically confirmed primary mitochondrial myopathy; elamipretide or placebo for 24 weeks.
Karaa A, Bertini E, Carelli V, et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial Neurology. PMID 37268435
- Randomized trial
39 people
Counts toward no label
Mitochondrial energetic capacity changed transiently. Absolute-change p = 0.055 and percentage-change p = 0.045; no difference at day seven or significant improvement in muscle fatigue resistance.
Adults aged 60–85 selected for poor mitochondrial function; a single infusion versus placebo.
Roshanravan B, Liu SZ, Ali AS, et al. (2021). In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial PLoS One. PMID 34264994
Read further
SS-31
Frequently asked questions
- Is SS-31 an approved anti-aging medicine?
- No. Elamipretide is approved as Forzinity for improving muscle strength in people with Barth syndrome weighing at least 30 kg. That indication does not establish an anti-aging or longevity benefit.
- Why is the approval described as accelerated?
- FDA relied on an intermediate measure, knee extensor muscle strength, considered reasonably likely to predict patient benefit. A confirmatory randomized trial is required to verify the benefit.
- Is an online SS-31 vial equivalent to Forzinity?
- The name alone cannot establish equivalence. A seller's label does not verify contents, concentration, sterility, quality or the formulation used in the approved medicine.